Tech Center 1600 • Art Units: 1636
This examiner grants 58% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 16476794 | IMMUNOENGINEERED PLURIPOTENT CELLS | Final Rejection | The Regents of the University of California |
| 18359665 | RIBOSWITCH MODULATED GENE THERAPY FOR RETINAL DISEASES | Non-Final OA | The Medical College of Wisconsin, Inc. |
| 17559926 | MAMMALIAN CELL LINES WITH SIRT-1 GENE KNOCKOUT | Final Rejection | Hoffmann-La Roche Inc. |
| 17300668 | METHODS AND COMPOSITIONS FOR EDITING NUCLEOTIDE SEQUENCES | Non-Final OA | Massachusetts Institute of Technology |
| 17047367 | THERAPEUTIC MODULATION OF TUMOR SUPPRESSORS USING EXOSOMES | Non-Final OA | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 19193454 | ISOLATED IMMUNE CELL EXPRESSING A RECEPTOR, INTERLEUKIN-7, AND CHEMOKINE (C-C MOTIF) LIGAND 19 | Final Rejection | NOILE-IMMUNE BIOTECH, INC. |
| 19083930 | ENGINEERED DNA MOLECULE FOR CODING RNA | Non-Final OA | RINUAGENE INTERNATIONAL HK LIMITED |
| 18053160 | GENE THERAPY CONSTRUCTS AND METHODS OF USE | Non-Final OA | Amicus Therapeutics, Inc. |
| 18449625 | GENETICALLY MODIFIED PRIMARY CELLS FOR ALLOGENEIC CELL THERAPY | Final Rejection | Sana Biotechnology, Inc. |
| 18006555 | LIPID NANOPARTICLE COMPRISING MODIFIED NUCLEOTIDES | Non-Final OA | STRAND THERAPEUTICS INC. |
| 17701325 | COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN B (APOB) GENE EXPRESSION | Non-Final OA | Omega Therapeutics, Inc. |
| 17362950 | METHODS FOR PRODUCING ISOBUTENE FROM 3-METHYLCROTONIC ACID | Final Rejection | Scientist of Fortune, S.A. |
| 16994283 | USE OF INHIBITORS OF IL-36 PROTEOLYTIC PROCESSING FOR THE TREATMENT AND/OR REDUCTION OF INFLAMMATION | Non-Final OA | THE PROVOST, FILLOWS, FOUNDATIO SCHOLARS, & THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy